相关实验视频

Updated: May 29, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

关于细胞受体激活在质母细胞瘤中的治疗潜力的进展

Gerson G Contreras-Chávez¹, Luis A Zapi-Colin¹, José A Estrada¹

¹Neurochemistry Laboratory, Faculty of Medicine, Universidad Autónoma del Estado de México, Toluca, México.

Molecular biology reports

|February 5, 2025

概括

多形质母细胞瘤是一种侵袭性脑癌,显示受体过度表达与糟糕的结果有关. 准这些受体可能会改善质母细胞瘤治疗和患者的存活率.

科学领域:

神经瘤学神经瘤学
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

多形质母细胞瘤是最具侵略性的原发性脑瘤,治疗选择有限,患者存活率低.
像EGFR,VEGFR和TLRs这样的受体的过度表达在质母细胞瘤中很常见,并影响瘤的进展.
这些受体在炎症,细胞生长和生存途径中发挥着关键作用,这些途径对于质母细胞瘤的发展至关重要.

研究的目的:

审查目前关于质母细胞瘤模式识别和氨酸激酶受体的临床前和临床研究.
研究这些受体在质母细胞瘤发育和进展中的作用.
探索向这些受体以改善质母细胞瘤治疗结果和生存的潜力.

主要方法:

临床前研究的系统审查.
对临床试验数据的分析.
在质母细胞瘤中寻找模式识别受体 (PRR) 和氨酸激酶受体 (TKR) 的文献搜索.

主要成果:

像EGFR和VEGFR这样的受体氨酸激酶 (RTK) 参与了质母细胞瘤的扩散和血管生成.
像托尔类受体 (TLRs) 这样的模式识别受体 (PRRs) 调节瘤微环境和免疫反应.
这些受体的调节失调对质母细胞瘤的发病有显著的贡献.

结论:

向EGFR,VEGFR和TLRs是质母细胞瘤的一种有前途的治疗策略.
对这些受体的复杂相互作用进行进一步的研究对于开发有效的治疗方法至关重要.
调节受体信号通路有可能提高质母细胞瘤患者的存活率.

关键词:

细胞信号通路是细胞信号通路.质母细胞瘤 (glioblastoma) 是一个

更多相关视频

Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window

Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window

Published on: November 20, 2012

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Enzyme-linked Receptors

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...